Photo of Huihui Ye,  MD

Huihui Ye, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-5828
Fax: (617) 975-5620


hye@bidmc.harvard.edu

Huihui Ye, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Instructor, Pathology, Harvard Medical School
  • Staff Pathologist, Pathology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a practicing Urological Pathologist at the Beth Israel Deaconess Medical Center. My main research interest is to study molecular characteristics of aggressive prostate cancer, to distinguish them from indolent ones, with an ultimately goal to increase early detection of aggressive prostate cancer and to improve management of patients with indolent cancer. In collaboration with Dr. Steven Balk, one of my main projects is to identify genetic characteristics of different Gleason grades of prostate cancer and to study molecular mechanisms of progression from low to high grade cancer. Another main project of mine is to study prognostic values of potential biomarkers for Gleason upgrading in active surveillance patients. Finally, I study resistant mechanisms in high risk prostate cancer that are treated with neoadjuvant intense androgen deprivation therapy.

Publications

Powered by Harvard Catalyst
  • Wu H, Sun Y, Ye H, Yang S, Lee SL, de Las Morenas A. Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets. Pathol Oncol Res 2015. PubMed
  • Chen E, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RT, Kantoff P, Montgomery B, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors. Clin Cancer Res 2014. PubMed
  • Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. J Clin Oncol 2014. PubMed
  • Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM, Robinson BD, Sanda MG, Chinnaiyan AM, Beltran H, Rubin MA, Mosquera JM. Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Hum Pathol 2014; 45:2136-43. PubMed
  • Brimo F, Xu B, Scarlata E, B├ęgin LR, Spatz A, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A. Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. Hum Pathol 2014; 45:2006-13. PubMed
  • Sun T, Ye H, Wu CL, Lee GS, Kantoff PW. Emerging players in prostate cancer: long non-coding RNAs. Am J Clin Exp Urol 2015; 2:294-9. PubMed
  • Sowalsky AG, Ye H, Bubley GJ, Balk SP. Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res 2013; 73:1050-5. PubMed
  • Ye H, Kong X, He TW, Jolis T, Choi K, Lepor H, Melamed J. Intraoperative frozen section analysis of urethral margin biopsies during radical prostatectomy. Urology 2011; 78:399-404. PubMed
  • Ye H, Walsh PC, Epstein JI. Skeletal muscle involvement by limited Gleason score 6 adenocarcinoma of the prostate on needle biopsy is not associated with adverse findings at radical prostatectomy. J Urol 2010; 184:2308-12. PubMed
  • Ye H, Li Y, Melamed J, Pearce P, Wei J, Chiriboga L, Wang Z, Osman I, Lee P. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer. J Urol 2009; 181:872-7. PubMed
  • Li Y, Li CX, Ye H, Chen F, Melamed J, Peng Y, Liu J, Wang Z, Tsou HC, Wei J, Walden P, Garabedian MJ, Lee P. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med 2009; 12:2790-8. PubMed